Synthesis of enantiopure 5.7-spirodiamines: (S)-1,7-diaza[4.6]undecane and related compounds
摘要:
The efficient synthesis of enantiomerically pure (S)-1,7-diaza[4.6]undecane and (S)-7-methyl-1,7-diaza[4.6]undecane and related compounds is reported. These novel diamines are obtained from (S)-proline, which is reacted with chloral to give an enantiomerically pure oxazolidinone, which is alkylated at the alpha-position using cis-1,4-clibromobutene. The resulting allylbromide is then reacted with ammonia or methylamine to yield, as intermediates, allylamines, which ring close to give the corresponding spirolactams. The parent and the 7-methyl (S)-5.7-spirodiamines are obtained via reduction in two steps of the spirolactams. The expected absolute configuration was confirmed by X-ray structural analysis. Enantiomeric excess (> 99.8% ee) was determined using the Mosher amides of the spirodiamines and gas chromatography. (c) 2005 Elsevier Ltd. All rights reserved.
Synthesis of enantiopure 5.7-spirodiamines: (S)-1,7-diaza[4.6]undecane and related compounds
摘要:
The efficient synthesis of enantiomerically pure (S)-1,7-diaza[4.6]undecane and (S)-7-methyl-1,7-diaza[4.6]undecane and related compounds is reported. These novel diamines are obtained from (S)-proline, which is reacted with chloral to give an enantiomerically pure oxazolidinone, which is alkylated at the alpha-position using cis-1,4-clibromobutene. The resulting allylbromide is then reacted with ammonia or methylamine to yield, as intermediates, allylamines, which ring close to give the corresponding spirolactams. The parent and the 7-methyl (S)-5.7-spirodiamines are obtained via reduction in two steps of the spirolactams. The expected absolute configuration was confirmed by X-ray structural analysis. Enantiomeric excess (> 99.8% ee) was determined using the Mosher amides of the spirodiamines and gas chromatography. (c) 2005 Elsevier Ltd. All rights reserved.
SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
申请人:Aptinyx Inc.
公开号:US20210047324A1
公开(公告)日:2021-02-18
Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be useful in the treatment of conditions such as depression and related disorders as well as other disorders.
[EN] SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS NMDA SPIRO-LACTAMES ET LEURS UTILISATIONS
申请人:APTINYX INC
公开号:WO2019152678A1
公开(公告)日:2019-08-08
Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be useful in the treatment of conditions such as depression and related disorders as well as other disorders.